---
company: Rezolute, Inc.
ticker: RZLT
form: 8-K
filed: 2026-11-05
accepted: 2026-11-05T21:14:30+00:00
accession: 0001104659-26-123336
source: https://www.sec.gov/Archives/edgar/data/1509261/000110465926123336/
---

# Rezolute (RZLT) Q1 2027 earnings

## Header

- Company: Rezolute, Inc.
- Reported: 2026-11-05 16:14 AMC ET
- Source: 8-K only — accession 0001104659-26-123336, Item 2.02 + Exhibit 99.1
- Verdict: Net loss narrowed to $18.5 million in Q1 FY2027, and cash declined to $90.0 million.

## Headline numbers

| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---:|---|---|
| EPS (GAAP) | -$0.18 | 0.0 pp | — | Ex. 99.1, income statement |

## Revenue breakdown

not stated in the 8-K

## Margins and costs

- Gross margin: not stated in the 8-K
- Operating expenses: $19.4 million (+2.2% YoY)
- One-offs in the quarter: not stated in the 8-K
- Effective tax rate: not stated in the 8-K
- Non-GAAP bridge: not stated in the 8-K

## KPIs

| Metric | Actual | Prior quarter | Prior year | Change |
|---|---:|---:|---:|---:|
| Cash and cash equivalents | $8.2 million | $10.6 million | — | -23.2% |
| R&D expenses | $12.8 million | $14.9 million | $13.1 million | -14.2% QoQ, -2.6% YoY |
| G&A expenses | $6.6 million | $6.7 million | $6.7 million | -1.1% QoQ, -1.3% YoY |
| Net loss | $18.5 million | $20.5 million | $18.2 million | -9.8% QoQ, +1.6% YoY |

## Guidance

not stated in the 8-K

## What drove it

- Revenue story: No revenue reported.
- EPS story: Net loss per share remained flat at -$0.18 YoY.
- One-off check: not stated in the 8-K

## The good

- R&D expenses decreased YoY and QoQ due to lower manufacturing and patient affairs costs.

## The bad

- Cash declined 23.2% sequentially to $8.2 million.
- Net loss widened slightly YoY to $18.5 million.

## The ugly

- none

## Open questions

- The release does not disclose the specific drivers of the sequential cash decline.
- The release does not provide a reconciliation of GAAP net loss to adjusted net loss.

## Full release

### Rezolute (RZLT) earnings release, November 5, 2026

Rezolute, Inc. (RZLT) · Form 8-K, Item 2.02 · Filed 2026-11-05 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123336/)

Rezolute Reports First Quarter Fiscal 2027 Financial

Results and Provides Business Update

REDWOOD

CITY, Calif., November 5, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today reported financial results and provided a business update for the first quarter ended September 30, 2026.

Tumor HI

Congenital HI

Business Update

First Quarter Fiscal 2027 Financial Results

Cash, cash equivalents and investments in marketable securities were $90.0 million as of September 30, 2026, compared with $107.8 million as of June 30, 2026.

Research and development (R&D) expenses were

$12.8 million for the first quarter of fiscal 2027, compared with $13.1 million for the same period a year ago. The decrease was primarily due to decreased manufacturing costs for ersodetug and patient affairs costs, partially offset by increased employee-related stock-based compensation expense. R&D expenses include $1.5 million of share-based compensation expense for the first quarter of fiscal 2027, compared with $1.2 million for the same period a year ago.

General and administrative (G&A) expenses were $6.6 million for the first quarter of fiscal 2027, compared with $6.7 million for the same period a year ago. The decrease was primarily attributable to a decrease in professional fees, partially offset by increased employee-related stock-based compensation expense. G&A expenses include $1.8 million of share-based compensation expense for the first quarter of fiscal 2027, compared with $1.4 million for the same period a year ago.

Net loss was $18.5 million for the first quarter of fiscal 2027 compared with a net loss of $18.2 million for the same period a year ago.

About Ersodetug

Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances (such as IGF-2) in the setting of hyperinsulinism (HI), thereby improving hypoglycemia. Because ersodetug acts downstream from pancreatic insulin or paraneoplastic IGF-2 secretion, and from entero-incretin pathways, it has the potential to be universally effective at treating refractory hypoglycemia due to any form of hyperinsulinism (HI), including congenital HI, tumor HI (insulinoma, non-islet cell tumors) or bariatric/non-bariatric gastrointestinal surgery hypoglycemia. Ersodetug for the treatment of HI is investigational. Statements about safety and efficacy have not been approved by any health authority.

About Rezolute, Inc.

Rezolute is a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of

HI.

For more information, visit www.rezolutebio.com.

Forward-Looking Statements

This release, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as "anticipate," "believe,"

"estimate," "expect," "intend," "plan," "project," "seek," "strive,"

"try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions.

These forward-looking statements include, but are not limited to, statements regarding the potential safety, efficacy and therapeutic and commercial potential of ersodetug for the treatment of hypoglycemia caused by hyperinsulinism; the timing and results of the Phase 3 upLIFT study of ersodetug in tumor HI, including our expectation to announce topline results by mid-December 2026; the predictive nature of the CGM data and other findings from the sunRIZE study and its ongoing open-label extension as they relate to the potential efficacy of ersodetug in treating hypoglycemia; the persuasiveness of the additional study data reviewed by FDA and the possibility of FDA agreeing to advance the congenital HI program notwithstanding the lack of statistical significance for the primary endpoint in the sunRIZE study; the Company’s plans and expectations regarding a pre-BLA meeting and the potential submission of a Biologics License Application (BLA) for ersodetug for one or both of tumor HI and congenital HI in 2027; the potential safety, efficacy and therapeutic potential of ersodetug for treating refractory hypoglycemia caused by any form of HI; and the commercial outlook and launch strategy for ersodetug, including the potential $5 billion combined market opportunity. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. With respect to congenital hyperinsulinism, although FDA has recommended that the

Company file a BLA for review for congenital HI after holding a pre-BLA meeting, there can be no assurance that FDA will agree that the totality of evidence from the sunRIZE program demonstrates a clinically meaningful benefit or is sufficient to support approval of ersodetug... (truncated)cipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include any other factors discussed in our filings with the SEC, including the Risk Factors contained in Rezolute’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the U.S. Securities and Exchange Commission’s website at www.sec.gov. You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement.

Rezolute Contacts:

Christen Baglaneas

Rezolute, Inc.

1411 Broadway, 16th Floor

New York, NY 10018 cbaglaneas@rezolutebio.com

508-272-6717

Carrie McKim

Rezolute, Inc.

1411 Broadway, 16th Floor

New York, NY 10018 cmckim@rezolutebio.com

336-608-9706

Rezolute, Inc.

Condensed Consolidated Financial Statements Data

(in thousands, except per share data)

#### Financial statements

##### Income Statement (Three Months Ended — (in thousands, except per share data))

| | Three Months Ended – September 30, – 2026 | Three Months Ended – September 30, – 2025 |
|---|---:|---:|
| **Operating expenses:** | | |
| Research and development | 12,807 | 13,149 |
| General and administrative | 6,578 | 6,668 |
| Total operating expenses | 19,385 | 19,817 |
| Loss from operations | -19,385 | -19,817 |
| Non-operating income, net | 898 | 1,667 |
| Net loss | -18,487 | -18,150 |
| Basic and diluted net loss per common share | -0.18 | -0.18 |
| Shares used to compute basic and diluted net loss per common share | 104,778 | 103,423 |

##### Balance Sheet (September 30, — (in thousands, except per share data))

| | September 30, – 2026 | June 30, – 2026 |
|---|---:|---:|
| **Condensed Consolidated Balance Sheets Data:** | | |
| Cash and cash equivalents | 8,150 | 10,615 |
| Investments in marketable debt securities | 81,849 | 97,186 |
| Working capital | 84,370 | 99,093 |
| Total assets | 96,010 | 112,849 |
| Accumulated deficit | -499,929 | -481,442 |
| Total stockholders’ equity | 85,948 | 100,687 |
